Input Symbol:

Show Other Options & Instructions

Month Back:
Owned(%):
Shares Outstanding(‱)
Transaction Code:

Instructions

Month Back: Display transaction record of previous n months.

Owned(%): Transaction shares relative to shares owned.

Shares Outstanding(‱): Transaction shares relative to shares outstanding.

Check Insider Trading for more details.

upgrade to Tier 1 to access blurred content, display up to 300 records, and unlimited CSV download

Data last updated 2024-04-28 04:05:40 -0500 US CDT

Insider Sentiment

Company Name Sector Industry Shares Outstanding(Mil) 52-week High/Low Period Acq/Dsp Transaction Countb Ids/Sec/Mkt Quantc Acq/Dsp Shares Amountb Acq/Dsp PctSOd
Ultragenyx Pharmaceutical Inc. Health Care Pharmaceuticals 82.11
31.5
55.0
44.2
 3-month 0 / 10
0 / 69133
0.0 / 0.1
6-month 0 / 11
0 / 99133
0.0 / 0.1

Data last updated 2024-04-27 07:55:23 -0500 US CDT

Major Shareholders

Shareholder Relation Report Date Holding Pct Sharesa Shares(Previous Report Date)a Transactions (3 month)b Transactions (6 month)b
Kakkis Emil D President & CEO 2024-03-05 3.4% 2827898 (0.9%, -0.1%) 2803755 (2024-02-08)
C: 0 / 1
S: 0 / 30000
P: NA / 45.0
C: 0 / 2
S: 0 / 60000
P: NA / 46.44
Tpg Group Holdings (Sbs) Advisors, Inc. Former 10% Owner (2)(3)(4)(5) 2014-07-14 3.2% 2596420 (-15.7%, NA%) 3085240 (2014-02-07)
Fmr Llc See Remark 1. 2014-08-05 1.8% 1457994 (-55.2%, NA%) 3260240 (2014-02-05)
Kassberg Thomas Richard CBO & EVP 2024-03-12 0.3% 252823 (-4.3%, 2.4%) 264332 (2024-03-05)
C: 0 / 2
S: 0 / 12520
P: NA / 50.24
C: 0 / 2
S: 0 / 12520
P: NA / 50.24
Aliski William Director 2021-06-28 0.2% 147655 (1.5%, NA%) 145510 (2021-02-23)
Horn Howard Chief Financial Officer 2024-03-05 0.1% 99766 (24.2%, 24.2%) 80336 (2023-10-10)
Sharp Shalini EVP, Finance 2020-10-16 0.1% 97812 (-0.3%, NA%) 98187 (2020-08-19)
Pinion John Richard See Remarks 2024-03-05 0.1% 89268 (19.4%, 19.4%) 74744 (2023-05-19)
C: 0 / 1
S: 0 / 4173
P: NA / 53.76
C: 0 / 1
S: 0 / 4173
P: NA / 53.76
Huang Dennis Karl See Remarks 2024-03-05 0.1% 83002 (28.3%, NA%) 64715 (2023-03-03)
Parschauer Karah Herdman EVP and Chief Legal Officer 2024-03-05 0.1% 67340 (29.5%, 29.5%) 51982 (2023-05-05)
C: 0 / 1
S: 0 / 3756
P: NA / 53.76
C: 0 / 1
S: 0 / 3756
P: NA / 53.76
Harris Erik EVP & Chief Commercial Officer 2024-03-05 0.1% 67163 (31.0%, 31.0%) 51281 (2023-09-06)
C: 0 / 1
S: 0 / 4768
P: NA / 53.76
C: 0 / 1
S: 0 / 4768
P: NA / 53.76
Crombez Eric EVP and Chief Medical Officer 2024-04-19 0.1% 48785 (-0.2%, 59.9%) 48927 (2024-03-05)
C: 0 / 2
S: 0 / 1380
P: NA / 52.77
C: 0 / 2
S: 0 / 1380
P: NA / 52.77
Huizenga Theodore Alan SVP, Chief Accounting Officer 2024-04-18 0.1% 41366 (0.0%, 48.3%) 41380 (2024-03-05)
C: 0 / 1
S: 0 / 341
P: NA / 53.76
C: 0 / 1
S: 0 / 341
P: NA / 53.76
Narachi Michael Director 2023-06-09 0.0% 21605 (21.8%, NA%) 17745 (2022-06-28)
Fust Matthew K Director 2024-03-11 0.0% 14860 (-45.0%, -45.0%) 27055 (2023-06-09)
C: 0 / 1
S: 0 / 12195
P: NA / 50.88
C: 0 / 1
S: 0 / 12195
P: NA / 50.88

a Total of direct and indirect accounts with percentage change comparing with (previous report, 3 months ago). The latter is NA when no change was found in the last 3 months.
Notice: Shares amount and percentage change 1) do not reflect intraday conversion and execution of derivative securities. 2) may subject to correction on amendment filing.
b Vital&Spontaneous transactions of the past 3 and 6 months, respectively. For acquisitions, code P (open market purchase), L (small acquisition), and I (at discretion of broker) are counted. For dispositions, code S (open market sell), D (sell back to issuer) and I (at discretion of broker) are counted. "C:" count of number of transactions. "S:" shares amount involved in corrresponding transactions. "P:" average per share price of the transactions (for reference only). Horizontal bar chart denotes shares amount of acquisitions and dispositions. Black thin bar is fixed size ruler for easy comparison between reporters.
c Quantile value of transaction count in b among industry peers, sector peers, and the market, respectively.
d Percentage of transaction shares amount to shares outstanding.
Notice: red exclamation mark (!) represents the reporter has Form 4 amendment filings in the latest three reports.

Non-derivative Transactions Chart

Tips: Click legend to show single series     Click any bar to highlight corresponding transaction records      what is this?




Non-derivative Transactions Table      CSV download

Tips: type "code_p" to show transactions with code "P".

Filing Date Transaction Date Operation Date Original Filing Reporter Relation Opr Amounta %(Owned)b ‱(SO)c Avg Prcd Account Type Full Name Code Remain Shares Outstanding (Million)e
2024-04-19 2024-04-18 2024-04-18 4 Crombez Eric EVP AND CHIEF MEDICAL OFFICER dsp 142.0 0.29 0.02 44.1 Direct Common Stock ULTRAGENYX PHARMACEUTICAL INC.

code_S

code  S 		48785.0 82.11 (RARE)
2024-04-18 2024-04-16 2024-04-16 4 Huizenga Theodore Alan SVP, CHIEF ACCOUNTING OFFICER dsp 14.0 0.03 0.0 42.31 Direct Common Stock ULTRAGENYX PHARMACEUTICAL INC.

code_F

code  F 		41366.0 82.11 (RARE)
2024-03-12 2024-03-11 2024-03-11 4 Kassberg Thomas Richard CBO & EVP dsp 11509.0 4.35 1.4 49.93 Direct Common Stock ULTRAGENYX PHARMACEUTICAL INC.

code_S

code  S 		252823.0 82.11 (RARE)
2024-03-11 2024-03-07 2024-03-07 4 Fust Matthew K DIRECTOR dsp 12195.0 45.07 1.49 50.88 Direct Common Stock ULTRAGENYX PHARMACEUTICAL INC.

code_S

code  S 		14860.0 thumbnail 82.11 (RARE)
2024-03-05 2024-03-01 2024-03-01 4 Horn Howard CHIEF FINANCIAL OFFICER acq 19400.0 19.45 2.36 0.0 Direct Common Stock ULTRAGENYX PHARMACEUTICAL INC.

code_A

code  A 		99766.0 82.11 (RARE)
2024-03-05 2024-03-01 2024-03-01 4 Pinion John Richard SEE REMARKS dsp 4233.0 4.53 0.52 53.76 Direct Common Stock ULTRAGENYX PHARMACEUTICAL INC.

code_F,S

code  F  S 		89268.0 thumbnail 82.11 (RARE)
2024-03-05 2024-03-01 2024-03-01 4 Pinion John Richard SEE REMARKS acq 18757.0 20.06 2.28 0.0 Direct Common Stock ULTRAGENYX PHARMACEUTICAL INC.

code_A

code  A 		93501.0 thumbnail 82.11 (RARE)
2024-03-05 2024-03-01 4 Kakkis Emil D PRESIDENT & CEO holding 2263985.0 0 275.71 0.0 See Fn Common Stock ULTRAGENYX PHARMACEUTICAL INC.

code_

NA 		82.11 (RARE)
2024-03-05 2024-03-01 2024-03-01 4 Kakkis Emil D PRESIDENT & CEO acq 41560.0 7.37 5.06 0.0 Direct Common Stock ULTRAGENYX PHARMACEUTICAL INC.

code_A

code  A 		563913.0 thumbnail 82.11 (RARE)
2024-03-05 2024-03-01 2024-03-01 4 Kakkis Emil D PRESIDENT & CEO dsp 17417.0 3.01 2.12 53.69 Direct Common Stock ULTRAGENYX PHARMACEUTICAL INC.

code_F

code  F 		560781.0 82.11 (RARE)
2024-03-05 2024-03-01 2024-03-01 4 Crombez Eric EVP AND CHIEF MEDICAL OFFICER dsp 1238.0 2.47 0.15 53.76 Direct Common Stock ULTRAGENYX PHARMACEUTICAL INC.

code_S

code  S 		48927.0 82.11 (RARE)
2024-03-05 2024-03-01 2024-03-01 4 Crombez Eric EVP AND CHIEF MEDICAL OFFICER acq 19400.0 38.87 2.36 0.0 Direct Common Stock ULTRAGENYX PHARMACEUTICAL INC.

code_A

code  A 		49912.0 82.11 (RARE)
2024-03-05 2024-03-01 2024-03-01 4 Parschauer Karah Herdman EVP AND CHIEF LEGAL OFFICER dsp 3756.0 5.28 0.46 53.76 Direct Common Stock ULTRAGENYX PHARMACEUTICAL INC.

code_S

code  S 		67340.0 82.11 (RARE)
2024-03-05 2024-03-01 2024-03-01 4 Parschauer Karah Herdman EVP AND CHIEF LEGAL OFFICER acq 18757.0 26.52 2.28 0.0 Direct Common Stock ULTRAGENYX PHARMACEUTICAL INC.

code_A

code  A 		70739.0 thumbnail 82.11 (RARE)
2024-03-05 2024-03-01 2024-03-01 4 Huang Dennis Karl SEE REMARKS acq 18757.0 22.47 2.28 0.0 Direct Common Stock ULTRAGENYX PHARMACEUTICAL INC.

code_A

code  A 		83472.0 thumbnail 82.11 (RARE)
2024-03-05 2024-03-01 2024-03-01 4 Huang Dennis Karl SEE REMARKS dsp 470.0 0.56 0.06 53.69 Direct Common Stock ULTRAGENYX PHARMACEUTICAL INC.

code_F

code  F 		83002.0 82.11 (RARE)
2024-03-05 2024-03-01 2024-03-01 4 Harris Erik EVP & CHIEF COMMERCIAL OFFICER acq 20357.0 28.42 2.48 0.0 Direct Common Stock ULTRAGENYX PHARMACEUTICAL INC.

code_A

code  A 		71638.0 thumbnail 82.11 (RARE)
2024-03-05 2024-03-01 2024-03-01 4 Harris Erik EVP & CHIEF COMMERCIAL OFFICER dsp 4768.0 6.63 0.58 53.76 Direct Common Stock ULTRAGENYX PHARMACEUTICAL INC.

code_S

code  S 		67163.0 82.11 (RARE)
2024-03-05 2024-03-01 2024-03-01 4 Kassberg Thomas Richard CBO & EVP acq 18757.0 7.06 2.28 0.0 Direct Common Stock ULTRAGENYX PHARMACEUTICAL INC.

code_A

code  A 		265617.0 thumbnail 82.11 (RARE)
2024-03-05 2024-03-01 2024-03-01 4 Kassberg Thomas Richard CBO & EVP dsp 1285.0 0.48 0.16 53.75 Direct Common Stock ULTRAGENYX PHARMACEUTICAL INC.

code_F,S

code  F  S 		264332.0 thumbnail 82.11 (RARE)
2024-03-05 2024-03-01 2024-03-01 4 Huizenga Theodore Alan SVP, CHIEF ACCOUNTING OFFICER acq 13950.0 33.34 1.7 0.0 Direct Common Stock ULTRAGENYX PHARMACEUTICAL INC.

code_A

code  A 		41842.0 82.11 (RARE)
2024-03-05 2024-03-01 2024-03-01 4 Huizenga Theodore Alan SVP, CHIEF ACCOUNTING OFFICER dsp 462.0 1.1 0.06 53.74 Direct Common Stock ULTRAGENYX PHARMACEUTICAL INC.

code_F,S

code  F  S 		41380.0 thumbnail 82.11 (RARE)
2024-02-08 2024-02-07 2024-02-07 4 Kakkis Emil D PRESIDENT & CEO dsp 30000.0 5.27 3.65 45.0 Direct Common Stock ULTRAGENYX PHARMACEUTICAL INC.

code_S

code  S 		539770.0 82.11 (RARE)
2024-02-08 2024-02-07 4 Kakkis Emil D PRESIDENT & CEO holding 2263985.0 0 275.71 0.0 By Emil Kakkis And Jenny Soriano Living Trust, Dated June 18, 200 Common Stock ULTRAGENYX PHARMACEUTICAL INC.

code_

NA 		82.11 (RARE)
2024-01-02 2023-12-29 2023-12-29 4 Kakkis Emil D PRESIDENT & CEO dsp 30000.0 5.0 3.65 47.87 Direct Common Stock ULTRAGENYX PHARMACEUTICAL INC.

code_S

code  S 		569770.0 82.11 (RARE)
2024-01-02 2023-12-29 4 Kakkis Emil D PRESIDENT & CEO holding 2263985.0 0 275.71 0.0 By Emil Kakkis And Jenny Soriano Living Trust, Dated June 18, 200 Common Stock ULTRAGENYX PHARMACEUTICAL INC.

code_

NA 		82.11 (RARE)
2024-01-02 2023-12-20 2023-12-20 to 2024-01-02 4 Huizenga Theodore Alan SVP, CHIEF ACCOUNTING OFFICER acq 4000.0 14.34 0.49 15.75 Direct Common Stock ULTRAGENYX PHARMACEUTICAL INC.

code_A,M

code  A  M 		27892.0 thumbnail 82.11 (RARE)

Derivative Transactions Chart

Tips: Click legend to show single series     Click any bar to highlight corresponding transaction records      what is this?






Derivative Transactions Table

Tips: type "code_m" to show transactions with code "M".

Filing Date Transaction Date Operation Date Original Filing Reporter Relation Opr Amounta %(Owned)b ‱(SO)c Avg Prcd Account Type Full Name Code Remain Shares Outstanding (Million)e
2024-03-05 2024-03-01 2024-03-01 4 Horn Howard CHIEF FINANCIAL OFFICER acq 34200.0 100.0 4.16 53.69 Direct Stock Option (Right To Buy) ULTRAGENYX PHARMACEUTICAL INC.

code_A

code  A 		34200.0 82.11 (RARE)
2024-03-05 2024-03-01 2024-03-01 4 Pinion John Richard SEE REMARKS acq 31400.0 100.0 3.82 53.69 Direct Stock Option (Right To Buy) ULTRAGENYX PHARMACEUTICAL INC.

code_A

code  A 		31400.0 82.11 (RARE)
2024-03-05 2024-03-01 2024-03-01 4 Kakkis Emil D PRESIDENT & CEO acq 70094.0 100.0 8.54 53.69 Direct Stock Option (Right To Buy) ULTRAGENYX PHARMACEUTICAL INC.

code_A

code  A 		70094.0 82.11 (RARE)
2024-03-05 2024-03-01 2024-03-01 4 Crombez Eric EVP AND CHIEF MEDICAL OFFICER acq 36551.0 100 4.45 54.57 Direct Stock Option (Right To Buy) ULTRAGENYX PHARMACEUTICAL INC.

code_A

code  A 		2351.0 thumbnail 82.11 (RARE)
2024-03-05 2024-03-01 2024-03-01 4 Parschauer Karah Herdman EVP AND CHIEF LEGAL OFFICER acq 31400.0 100.0 3.82 53.69 Direct Stock Option (Right To Buy) ULTRAGENYX PHARMACEUTICAL INC.

code_A

code  A 		31400.0 82.11 (RARE)
2024-03-05 2024-03-01 2024-03-01 4 Huang Dennis Karl SEE REMARKS acq 31400.0 100.0 3.82 53.69 Direct Stock Option (Right To Buy) ULTRAGENYX PHARMACEUTICAL INC.

code_A

code  A 		31400.0 82.11 (RARE)
2024-03-05 2024-03-01 2024-03-01 4 Harris Erik EVP & CHIEF COMMERCIAL OFFICER acq 34200.0 100.0 4.16 53.69 Direct Stock Option (Right To Buy) ULTRAGENYX PHARMACEUTICAL INC.

code_A

code  A 		34200.0 82.11 (RARE)
2024-03-05 2024-03-01 2024-03-01 4 Kassberg Thomas Richard CBO & EVP acq 31400.0 100.0 3.82 53.69 Direct Stock Option (Right To Buy) ULTRAGENYX PHARMACEUTICAL INC.

code_A

code  A 		31400.0 82.11 (RARE)
2024-03-05 2024-03-01 2024-03-01 4 Huizenga Theodore Alan SVP, CHIEF ACCOUNTING OFFICER acq 10551.0 100 1.28 56.74 Direct Stock Option (Right To Buy) ULTRAGENYX PHARMACEUTICAL INC.

code_A

code  A 		2351.0 thumbnail 82.11 (RARE)
2024-01-02 2023-12-20 2024-01-02 4 Huizenga Theodore Alan SVP, CHIEF ACCOUNTING OFFICER dsp 3000.0 100.0 0.37 21.0 Direct Stock Option (Right To Buy) ULTRAGENYX PHARMACEUTICAL INC.

code_M

code  M 		0.0 82.11 (RARE)
Form 3      CSV download
Filing Date Date requiring statement Form Type Reporter Relation Amounta ‱(SO)c Avg Excercisable Prcd Account Type Full Name Shares Outstanding (Million)e

a Sum of same type of securities in the form
b Relative to reporter's shares owned before (disposition) or after (acquisition) operation
c Relative to issuer's shares outstanding (1/10000)
d Average price for securities of the same type. Check the original form for detailed prices of multiple transactions
e Documented shares outstanding closest to the transaction date
Note: Corporate may change mapped CIK when merge or spin-off happen. Please report error if the ticker you searched for does not have up-to-date insider trading information.
Show up to 30 records per table for current tier. (Access Guide)